Literature DB >> 17534814

Ocular symptoms and signs with preserved and preservative-free glaucoma medications.

N Jaenen1, C Baudouin, P Pouliquen, G Manni, A Figueiredo, T Zeyen.   

Abstract

PURPOSE: To compare the prevalence of side effects between eyedrops with or without preservatives, in terms of subjective symptoms and objective signs in patients with open-angle glaucoma.
METHODS: In a multicenter cross-sectional epidemiologic survey in four European countries, ophthalmologists in private practice enrolled 9658 nonconsecutive patients using preservative (P) or preservative-free (PF) beta-blocking eyedrops between June 1997 and December 2003. Subjective symptoms, conjunctival and palpebral signs, and superficial punctate keratitis were explored before and after a change in therapy. For statistical analysis, a Chi-square test was used to calculate the differences in the prevalence of symptoms and signs with or without preservatives.
RESULTS: A total of 74% of the patients used P, 12% PF, 10% a P-PF combination, and in 4% the type of medication was unknown. Each recorded symptom and all the palpebral, conjunctival, and corneal signs were significantly more frequent (p<0.0001) in the P-group than in the PF-group, such as pain or discomfort during instillation (48 vs 19%), foreign body sensation (42 vs 15%), stinging or burning (48 vs 20%), and dry eye sensation (35 vs 16%). A total of 68% of the patients had a sec-ond visit performed, of whom 63% (6083) had been evaluated on treatment difference. A significant decrease (p<0.0001) of all ocular symptoms and signs was observed in patients in whom the preserved eyedrops were diminished in number or altered into preservative free drops.
CONCLUSIONS: Compared to preserved eyedrops, preservative free eyedrops are significantly less associated with ocular symptoms and signs of irritation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17534814     DOI: 10.1177/112067210701700311

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  108 in total

1.  Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT™) in patients with elevated intraocular pressure in a randomized clinical trial.

Authors:  Arthur Shedden; Ingrid A Adamsons; Albert J Getson; Jean K Laurence; Christopher R Lines; David J Hewitt; Tony W Ho
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-05-02       Impact factor: 3.117

2.  [Preservative-free glaucoma treatment : Selection of the correct treatment in 1 min].

Authors:  S Pfennigsdorf; P Eschstruth
Journal:  Ophthalmologe       Date:  2016-05       Impact factor: 1.059

Review 3.  Benzalkonium chloride and glaucoma.

Authors:  Carol A Rasmussen; Paul L Kaufman; Julie A Kiland
Journal:  J Ocul Pharmacol Ther       Date:  2013-11-08       Impact factor: 2.671

4.  Barriers to Glaucoma Medication Compliance Among Veterans: Dry Eye Symptoms and Anxiety Disorders.

Authors:  Jack Stringham; Noy Ashkenazy; Anat Galor; Sarah R Wellik
Journal:  Eye Contact Lens       Date:  2018-01       Impact factor: 2.018

5.  Switch from BAK-preserved to preservative-free latanoprost decreases anterior chamber flare in POAG patients.

Authors:  Ph A Kestelyn; Ph G Kestelyn; D De Bacquer; A M Stevens
Journal:  Int Ophthalmol       Date:  2017-12-22       Impact factor: 2.031

Review 6.  Ocular surface - a complex and vulnerable adoptive environment for topical glaucoma treatment.

Authors:  Vasile Potop
Journal:  Rom J Ophthalmol       Date:  2016 Jul-Sep

7.  Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%.

Authors:  Quang H Nguyen; Matthew G McMenemy; Tony Realini; Jess T Whitson; Stephen M Goode
Journal:  J Ocul Pharmacol Ther       Date:  2013-02-20       Impact factor: 2.671

8.  Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits.

Authors:  Abayomi B Ogundele; Guangming Li; Joel J Ellis
Journal:  Clin Ophthalmol       Date:  2010-02-18

9.  Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assay.

Authors:  Hong Liang; Christophe Baudouin; Marie-Odile Faure; Grégory Lambert; Françoise Brignole-Baudouin
Journal:  Mol Vis       Date:  2009-08-25       Impact factor: 2.367

10.  Role of fixed-combination brinzolamide 1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.

Authors:  Henny J M Beckers; Jan Sag Schouten; Carroll A B Webers
Journal:  Clin Ophthalmol       Date:  2009-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.